Suffering an Unfair Job Loss is Tough, our california employment attorneys can help.

Yasmin Lawsuits: Products Liability Settlements Have Cost Bayer $142M in the US So Far

December 31, 1969

As of the end of April, Bayer AG had paid $142M to settle products liability lawsuits in the US accusing the drug manufacturer of making contraception that can cause potentially deadly blood clots. The 651 already resolved complaints have cost the German manufacturer about $218,000 on average. More than 11,000 other dangerous drug complaints over the Yasmin and Yaz birth control pills have been submitted.

A lot of these injury lawsuits started to come in beginning in 2009, in the wake of the Food and Drug Administration's report that between 2004 and 2008 at least 50 fatalities have been linked to Yaz and Yasmin. Many of the products liability complaints are accusing Bayer of marketing Yasmin and Yaz for unapproved uses and misleading women about the risks involved in taking these pills. "Failure to warn users about the risks involved in taking a drug can prove dangerous, potentially even fatal," said Anaheim personal injury lawyer Vincent Howard. "Not warning about possibly deadly side effects can be considered a marketing defect and may be grounds for a California Yasmin/Yaz lawsuit if serious injuries or death result."

In 2011, Yasmin was the number four contraceptive in this country and it has made several billions of dollars in revenue for Bayer over the years. The birth control pill was approved by the Food and Drug Administration over 10 years ago. A few years later, Bayer introduced Yaz, a similar type of birth control pill.

Some of the serious side effects reported from using Yasmin:
• Strokes
• Heart attacks
• Kidney damage
• Death
• Liver tumors
• Circulatory conditions
• Gallbladder problems
• Deep Vein thrombosis
• Pulmonary embolisms

Deep vein thrombosis and pulmonary embolisms are caused by blood clots that develop inside the human tissue, usually in the legs. In the event that these clots were to make their way through the blood stream and end up in the lungs, they can become pulmonary embolisms. Bayer has been clear to point out that it is only settling injury claims involving venous clot injuries (pulmonary embolism and deep vein thrombosis).

In Orange County, Los Angeles County, Riverside County, and San Bernardino County, Howard Law, PC partner and Anaheim Yasmin/Yaz lawyer Vincent Howard would be happy to offer you a free case evaluation to find out whether you have grounds for a case against Bayer.

Bayer Yasmin Lawsuit Settlements Climb To $142 Million, Bloomberg, April 26, 2012

FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing, FDA, April 10, 2012

More Blog Posts:
Yasmin/Yaz Birth Control Pills: FDA Advisory Panel Advises Including Blood Clot Warning on Their Labels, California Injury Lawyers, December 31, 2011

$48.1M Los Angeles Products Liability Verdict Awarded to Man That Took Motrin and Developed SJS and TEN, California Injury Lawyers, October 7, 2011

FDA Wants Transvaginal Mesh Device Makers to Study Related Health Complications, California Injury Lawyers, January 11, 2012

Last month, the FDA announced that it had finished its evaluation of a number of observational studies looking into the blood clot risk involved in taking birth control pills with drospirenone, which is a synthetic version of progesterone, the female hormone. The FDA has concluded that contraceptive pills with drospirenone can be associated with a greater blood clot risk than other pills with progestin. The federal agency now wants these findings added to the labels of Yaz and Yasmin, as well as the contraceptive pills Safyral and Beyaz. This initiative comes just four months after an FDA advisory panel recommended that Yasmin and Yaz birth control labels come with a warning that their use may up the risk of a user developing potentially deadly blood clots.

Contact Howard Law, PC, and ask for your free case evaluation with Los Angeles Yasmin lawyer Vincent Howard.